A clinical trial to study the effect of two drugs Lignocaine and Dexmedetomidine on surgical bleed in trans-nasal endoscopic surgeries.

Surgical Field Quality In Trans-nasal Endoscopic Surgeries Using Lignocaine Infusion And Dexmedetomidine Infusion. A Prospective Randomized Control Study.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/11/010557

Enrollment

Registered

2017-11-20

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Surgical field quality in patients undergoing elective trans-nasal endoscopic surgeries.

Interventions

Intervention1: Lignocaine Infusion: A loading dose of 1.5 mg/kg following a loading dose for the duration of the surgery. Control Intervention1: Dexmedetomidine Infusion: A loading dose of 1microgram/

Eligibility

Inclusion criteria

Inclusion criteria: 1.ASA I And II 2.Patients undergoing elective trans-nasal endoscopic surgeries

Exclusion criteria

Exclusion criteria: Patients with: 1.Known cerebro-vascular disease 2.Known coagulation defects 3.Known hypersensativity to the drug. 4.History of hepatic or renal insufficiency 5.Body mass index >35 6.Poorly controlled hypertension 7.Use of beta-blockers 8.History of bradycardia episodes/atrio-venticular block and conduction defects.

Design outcomes

Primary

Measure	Time frame
To assess if intravenous Lignocaine infusion provides better surgical field as compared to Dexmedetomidine in patients undergoing elective trans-nasal endoscopic surgeries.Timepoint: At 30 mins interval from intubation	—

Secondary

Measure	Time frame
Estimated total blood loss.Timepoint: At the end of the surgery.;Requirement of other agents for controlled hypotension with their doses.Timepoint: 1.At baseline 2.After intubation 3.2 mins after local adrenaline instillation. 4.At 15 mins interval from the intubation time. ;Variations in hemodynamic parameters such as heart rate and blood pressure.Timepoint: 1.At baseline 2.After intubation 3.2 mins after local adrenaline instillation. 4.At 15 mins interval from the intubation time.	—

Measure

Time frame

Estimated total blood loss.Timepoint: At the end of the surgery.;Requirement of other agents for controlled hypotension with their doses.Timepoint: 1.At baseline 2.After intubation 3.2 mins after local adrenaline instillation. 4.At 15 mins interval from the intubation time. ;Variations in hemodynamic parameters such as heart rate and blood pressure.Timepoint: 1.At baseline 2.After intubation 3.2 mins after local adrenaline instillation. 4.At 15 mins interval from the intubation time.

—

Countries

India

Contacts

Public ContactDr Prachi Agrawal

PGIMER Chandigarh

amarjyoti28@rediffmail.com9990238972

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026